Entero Healthcare Solutions Limited has informed the Exchange regarding Appointment of Ms Sandhya Gadkari Sharma as Non- Executive Independent Director of the company w.e.f. August 25, 2026.
ENTERO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Entero Healthcare reported strong FY26 consolidated results with revenue of Rs. 65,912 million, up 29% from Rs. 50,958 million in FY25. Net profit for the year stood at Rs. 1,458 million versus Rs. 1,074 million, with EPS of Rs. 26.44. The Board re-appointed three Non-Executive Independent Directors—Mr. Sujesh Vasudevan, Mr. Rajesh Shashikant Dalal, and Ms. Sandhya Gadkari Sharma—for a second term of five years starting August 25, 2026, subject to shareholder approval. The company also approved allotment of 7,240 equity shares under its ESOP plan and granted 7,300 fresh stock options. Additionally, the Board approved acquisition of Vishal Surgicals and Vishal Surgicals & Medicals through subsidiary Sai Pharma Distributors Private Limited via Business Transfer Agreement. The 8th AGM is scheduled for August 19, 2026.
The 29% revenue growth and improved profitability indicate strong operational performance. The re-appointment of independent directors maintains board stability and governance continuity. The acquisition and ESOP activities demonstrate continued expansion and employee retention focus.